Julián Panés

Julián Panés

Auto-generated profile, based on publicly available information

Julián Panés

Department of Gastroenterology, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2010 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
AFAndre Franke
Andre Franke
DMDermot P B McGovern
Dermot P B McGovern
JBJeffrey C Barrett
Jeffrey C Barrett
KWKai Wang
Kai Wang
GRGraham L Radford-Smith
Graham L Radford-Smith
MPMiles Parkes
Miles Parkes

1 September 2015 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
Laurent Peyrin-birouletLaurent Peyrin-biroulet
Laurent Peyrin-biroulet
WSW Sandborn
W Sandborn
BSB E Sands
B E Sands
WRW Reinisch
W Reinisch
WBW Bemelman
W Bemelman
JCJ -F Colombel
J -F Colombel
OBJECTIVES:The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program was initiated by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). It examined potential treatment targets for inflammatory bowel disease (IBD) to be used for a “treat-to-ta

6 February 2011 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CACarl A Anderson
Carl A Anderson
GBGabrielle Boucher
Gabrielle Boucher
CLCharlie W Lees
Charlie W Lees
AFAndre Franke
Andre Franke
MDMauro D'Amato
Mauro D'Amato
JRJohn D Rioux
John D Rioux
John Rioux and colleagues report results of a large genome-wide association meta-analysis and follow-up study of ulcerative colitis. They identify 29 new risk loci for this inflammatory disease and show that many risk loci are shared between ulcerative colitis and Crohn's disease. Genome-wide association studies and candidate gene studies in ulcerative colitis have identified 18 susceptibility loci. We conducted a meta-analysis of six ulcerative colitis genome-wide association study datasets, comprising 6,687 cases and 19,718 controls, and followed up the top association signals in 9,628 cases and 12,917 controls. We identified 29 additional risk loci (P < 5 × 10−8), increasing the number of ulcerative colitis–associated loci to 47. After annotating associated regions using GRAIL, expression quantitative trait loci data and correlations with non-synonymous SNPs, we identified many candidate genes that provide potentially important insights into disease pathogenesis, including IL1R2, IL8RA-IL8RB, IL7R, IL12B, DAP, PRDM1, JAK2, IRF5, GNA12 and LSP1. The total number of confirmed inflammatory bowel disease risk loci is now 99, including a minimum of 28 shared association signals between Crohn's disease and ulcerative colitis.

1 September 2016 in The Lancet
Verified
Journal Article
Closed access
JPJulián Panés
Julián Panés
Damián García-OlmoDamián García-Olmo
Damián García-Olmo
GAGert Van Assche
Gert Van Assche
JCJean Frederic Colombel
Jean Frederic Colombel
WRWalter Reinisch
Walter Reinisch
SDSilvio Danese
Silvio Danese

1 February 2010 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
GAGert Van Assche
Gert Van Assche
ADAxel Dignass
Axel Dignass
JPJulian Panes
Julian Panes
LBLaurent Beaugerie
Laurent Beaugerie
JKJohn Karagiannis
John Karagiannis
F(For The European Crohn'S And Colitis Organisation (Ecco)
For The European Crohn'S And Colitis Organisation (Ecco)

16 August 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
WSWilliam J. Sandborn
William J. Sandborn
SGSubrata Ghosh
Subrata Ghosh
JPJulian Panes
Julian Panes
IVIvana Vranic
Ivana Vranic
CSChinyu Su
Chinyu Su
WNWojciech Niezychowski
Wojciech Niezychowski
Ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments are not universally effective. One additional treatment may be tofacitinib (CP-690,550), an oral inhibitor of Janus kinases 1, 2, and 3 with in vitro functional specificity for kinases 1 and 3 over kinase 2, which is expected to block signaling involving gamma chain–containing cytokines including interleukins 2, 4, 7, 9, 15, and 21. These cytokines are integral to lymphocyte activation, function, and proliferation. In a double-blind, placebo-controlled, phase 2 trial, we evaluated the efficacy of tofacitinib in 194 adults with moderately to severely active ulcerative colitis. Patients were randomly assigned to receive tofacitinib at a dose of 0.5 mg, 3 mg, 10 mg, or 15 mg or placebo twice daily for 8 weeks. The primary outcome was a clinical response at 8 weeks, defined as an absolute decrease from baseline in the score on the Mayo scoring system for assessment of ulcerative colitis activity (possible score, 0 to 12, with higher scores indicating more severe disease) of 3 or more and a relative decrease from baseline of 30% or more with an accompanying decrease in the rectal bleeding subscore of 1 point or more or an absolute rectal bleeding subscore of 0 or 1. The primary outcome, clinical response at 8 weeks, occurred in 32%, 48%, 61%, and 78% of patients receiving tofacitinib at a dose of 0.5 mg (P=0.39), 3 mg (P=0.55), 10 mg (P=0.10), and 15 mg (P1) at 8 weeks occurred in 13%, 33%, 48%, and 41% of patients receiving tofacitinib at a dose of 0.5 mg (P=0.76), 3 mg (P=0.01), 10 mg (P<0.001), and 15 mg (P<0.001), respectively, as compared with 10% of patients receiving placebo. There was a dose-dependent increase in both low-density and high-density lipoprotein cholesterol. Three patients treated with tofacitinib had an absolute neutrophil count of less than 1500. Patients with moderately to severely active ulcerative colitis treated with tofacitinib were more likely to have clinical response and remission than those receiving placebo. (Funded by Pfizer; ClinicalTrials.gov number, NCT00787202.)